Buy, Sell or Hold: Medtronic Inc (MDT-N) — Stock Predictions at Stockchase

skip to content

Home Daily Stock Opinions and Ratings Medtronic Inc (MDT-N)

NYSE:MDT

80.62

1.44 (1.82%) 1d

BUY

A generative AI play

They specialize in surgical robots and tools, implants and patient monitoring systems. Are partnering with Nvidia to build an AI platform for medical devices, like the recently approved first AI-enabled colonoscopy tool that could detected cancer. This gives MDT new hope, new life.

biotechnology / pharmaceutical

DON'T BUY

Covid turned everything on its head. Surgeries have been put off. Revenues, cashflow, and earnings have gone flat. We need the catalyst of more procedures and loosening of the hospital system, he doesn't know when this will happen. A fine company, but it's hard to predict when reality might change.

biotechnology / pharmaceutical

TOP PICK

46 years of raising the dividend and will continue. Shares have fallen off recently though. Balance sheet is strong and has a record of tuck-in acquisitions. Buy and hold a long time. (Analysts’ price target is $90.54)

biotechnology / pharmaceutical

WATCH

Likes healthcare. Not performing as well as peers. 200-day MA is falling, price is below. Not executing well. 15x forward earnings for a weak 5% growth rate. Wait to see if it shows better technical strength. Don't buy it just for the yield of 3.4%.

biotechnology / pharmaceutical

premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Aug 09/22, Down 15.1%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MDT has triggered its stop at $79. To remain disciplined, we recommend covering the position at this time.

biotechnology / pharmaceutical

BUY

Aging demographics help. It's selling below 2x below its 5-year average, and has a 6% operating cash flow yield. He expects solid earnings next week.

biotechnology / pharmaceutical

premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly This $124 billion market cap manufacturer of medical devices ranging from insulin pumps to pacemakers is the world's largest in its class. It has raised dividends for 46 consecutive years. It has been buying back stock while maintaining steady cash reserves and trades at just 2.4x earnings. The resumption in surgical procedures as the pandemic calms down is expected to lead to substantial uplift in EPS going forward. We recommend setting a stop loss at $79, looking to achieve $117 -- upside over 25%. Yield 2.92% (Analysts’ price target is $117.13)

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Jan 15/21, Down 7%) Company has increased dividend for almost 50 years, however needs a good acquisition to grow. Stock price is low which creates a buying opportunity. Will continue to buy and hold.

biotechnology / pharmaceutical

HOLD

Relatively low growth at 3-5%, value stock with a 13.5-14.5x multiple. Couple of missteps. Competitive threats. One of the largest medical device companies. Tends to attract money flows when markets get volatile. Reports later in February. Mild inflationary pressures. OK dividend. OK to hold over time, but if you want more growth, pair it with something like BSX.

biotechnology / pharmaceutical

SELL

They've been executing badly. Sell this and buy EW-N

biotechnology / pharmaceutical

WAIT

MDT vs. BSX Two great companies. In the implantable medical device business. Loves the area. Too expensive, as investors have flocked to them and the multiple has increased. Would love to own both if prices came down substantially.

biotechnology / pharmaceutical

BUY

Healthcare is an interesting area, especially with a slant toward medical devices. This is a safe and steady name, significant track record of dividend increases.

biotechnology / pharmaceutical

BUY

They report Thursday. Boring, but he predicts stellar numbers. Their medical devices are being installed in record numbers post-pandemic. There's a lot of pent-up demand from all these delayed surgeries.

biotechnology / pharmaceutical

BUY on WEAKNESS

Allan Tong’s Discover Picks Up 14.68% since August 18, 2020 MDT was trading at $101. It has since climbed as high as $122.15, but now lockdowns are delaying elective surgeries, and the stock is starting to wobble around $117. Keep an eye on this, because continuing lockdowns and a general market pullback would make this a buy again. Right now, MDT is pricey, trading at a 43x PE, which is nearly double from last April and the highest level in 12 months. Its divvy pays nearly 2%. Analysts target the stock at $129.26, based on 17 buys and three holds. Read 2 Successful Past Picks: Nuvei & Medtronic for our full analysis.

biotechnology / pharmaceutical

TOP PICK

The global leader in med-tech space by revenue. It has increased dividends for 42 consecutive years. 9.4% total return for the last 5 years. Benefits from the aging demographics. Does a lot of tuck in acquisitions. The top line is growing at 9% in the last 10 years. (Analysts’ price target is $128.84)

biotechnology / pharmaceutical

Showing 1 to 15 of 102 entries

«
‹
1
2
3
4
5
›
»

Next Page

Medtronic Inc(MDT-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 3

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 4

Stockchase rating for Medtronic Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Medtronic Inc(MDT-N) Frequently Asked Questions

What is Medtronic Inc stock symbol?

Medtronic Inc is a American stock, trading under the symbol MDT-N on the New York Stock Exchange (MDT). It is usually referred to as NYSE:MDT or MDT-N

Is Medtronic Inc a buy or a sell?

In the last year, 4 stock analysts published opinions about MDT-N. 3 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Medtronic Inc.

Is Medtronic Inc a good investment or a top pick?

Medtronic Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Medtronic Inc.

Why is Medtronic Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Medtronic Inc worth watching?

4 stock analysts on Stockchase covered Medtronic Inc In the last year. It is a trending stock that is worth watching.

What is Medtronic Inc stock price?

On 2023-03-31, Medtronic Inc (MDT-N) stock closed at a price of $80.62.

You may also like:

ABN-N HBR-T FIL-T CNHI-Q LSI-X LV-T USCO-X FL-X MVK-N CHN-N

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

© Stockchase Inc.